What may be driving Eli Lilly shares lower — plus, oil, financial stocks rally

Every weekday, CNBC Investment Club with Jim Cramer publishes Homestretch, an actionable afternoon update just in time for the final hour of trading on Wall Street. Market update: Stocks are higher for the second session in a row. Energy is a big story on Monday; oilfield services, refineries and two major companies, Exxon Mobil and Chevron, are coming together with the idea that they will benefit from the rebuilding of Venezuela's oil infrastructure after the events of the weekend. Financials are also having a strong period, with Goldman Sachs, Wells Fargo and Capital One reaching new highs. BlackRock also outperformed but we decided to sell part of the position to rebuild our cash position. Healthcare: One of the sectors left out of the rally is healthcare. Danaher is having a good session, but pharmaceutical and biotech stocks are taking a hit. Eli Lilly, Bristol Myers, AbbVie, Johnson & Johnson and Amgen fell between 1% and 4%. One reason for Lilly's decline may be news from its main rival, Novo Nordisk. The Danish pharmaceutical company officially launched its oral GLP-1 weight loss pill in the United States on Monday. The announcement comes as no surprise, and Eli Lilly is expected to launch its own orforgliprone within the next few months, which was submitted to the FDA for approval last month. In a note published Monday, Wolfe Research said it expects orforglipron to be available in the first quarter and forecasts full-year sales of $3.3 billion. Oral medications have many benefits over injections, so we are optimistic about GLP-1 adoption this year. The pills appeal to those who are afraid of taking injections. They are also easier to transport and store than injectable drugs, which often require refrigeration. The next event we're tracking for the group is the annual JPMorgan Healthcare Conference, which starts next Monday. All three healthcare companies in the portfolio are scheduled to present at the event, which typically includes updates on acquisitions, partnerships and fourth-quarter earnings pre-announcements. Next up: No significant gains after Monday's closing bell or before Tuesday's opening bell. A light day on the data side with just the S&P Global US Services PMI. (See here for a complete list of stocks in Jim Cramer's Charitable Trust.) When you subscribe to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trading alert before buying or selling a stock in his charitable foundation's portfolio. If Jim talked about a stock on CNBC TV, he waits 72 hours after issuing the trading alert before executing the trade. THE ABOVE INVESTMENT CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, TOGETHER WITH THE DISCLAIMERS. NO CIVIL OBLIGATIONS OR DUTIES EXIST OR SHALL BE RESULTING FROM YOUR RECEIVING ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULT OR PROFIT GUARANTEE IS MADE.